Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cisplatin + Gemcitabine + Necitumumab & Non-small-cell lung cancer (NSCLC) (Squamous Cell Carcinoma), the FDA approved Cisplatin + Gemcitabine + Necitumumab on November 24, 2015, for first-line treatment of metastatic Non-small-cell lung cancer (NSCLC) (Squamous Cell Carcinoma). Approval stemmed from the phase 3 SQUIRE trial (N=1093), showing improved overall survival (11.5 vs. 9.9 months; HR 0.84). It is explicitly not indicated for [Non-small-cell lung cancer (NSCLC) (Non-squamous Cell Carcinoma).](brain://O8MCUQOj0k-D2iiZ3-4KJg/NonsmallcellLungCancerNsclcNonsquamousCellCarcinom…